stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Total debt
Arcus Biosciences, Inc.'s total debt at the end of fiscal 2025 was $99.0M, up 106.3% from $48.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $102.0M. Over the past ten years it has ranged from $15.0M (fiscal 2020) to $117.0M (fiscal 2022); the current reading is higher than 60% of that period. Arcus Biosciences, Inc. ranks 86th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $99.0M | 106.25% |
| FY2024 | $48.0M | (58.97%) |
| FY2022 | $117.0M | 0.00% |
| FY2021 | $117.0M | 680.00% |
| FY2020 | $15.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $102.0M | 0.99% |
| Jun 2026 | $101.0M | 1.00% |
| Mar 2026 | $100.0M | 1.01% |
| Dec 2025 | $99.0M | 1.02% |
| 15 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR compare | $252.4M |
| XNCR Xencor, Inc. compare | $119.7M |
| RCUS Arcus Biosciences, Inc. | $102.0M |
| BEAM Beam Therapeutics Inc. compare | $100.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| PHVS Pharvaris N.V. compare | $559.6K |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| RXRX Recursion Pharmaceuticals, Inc. compare | $93.0K |
| MBX MBX Biosciences, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement